Leading vaccine maker Bharat Biotech (Krishna Ella - Chairman and Managing Director, Suchitra Ella - Chairperson) on Friday received the
National Technology Award for 2018 from the Central government’s Technology
Development Board for its Rotavac vaccine.
This prestigious award for innovative technologies,
successfully developed and commercialized from India, was presented by
President Ram Nath Kovind at the Technology Day ceremony held at Vigyan in New
Delhi.
Launched in 2015 Rotavac was introduced into the Universal
Immunization Programme (UIP) in India during 2016, with initial implementation
in 9 states. Till date, Bharat Biotech
has supplied about 35 million doses to the UIP.
The vaccine is already saving infant lives and lowering the
cost of hospitalizations across India.
The company has also initiated supply of WHO Prequalified
Rotavac to UNICEF and other Immunization programmes worldwide, the
Hyderabad-based company said in a statement.
“We are proud to receive the National Technology Award 2018
for ROTAVAC, it proves that researchers and product developers from India are
capabable to develop and commercialize innovative technologies for the world,”
said Krishna M Ella, Chairman and Managing Director, Bharat Biotech.
The national award from the Technology Development Board
award recognizes organizations, who have forged powerful partnerships with the
national laboratories and to create knowledge networks with academic
institutions to promote research and development and to gain entry into global
markets.
Rotavac boasts a large family of intellectual property with
patents filed in more than 35 countries and granted in 10 countries including
India, USA, China, EU, Japan, and Britain. Bharat Biotech currently, holds a
portfolio of 60 patents and has delivered more than 3 billion doses of vaccines
to over 65 countries.
Comments